HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells.

Abstract
Cancer vaccines have now demonstrated clinical efficacy, but immune modulatory mechanisms that prevent autoimmunity limit their effectiveness. Systemic administration of mAbs targeting the immune modulatory receptors CTLA-4 and glucocorticoid-induced TNFR-related protein (GITR) on Treg and effector T cells augments anti-tumor immunity both experimentally and clinically, but can induce life-threatening autoimmunity. We hypothesized that local delivery of anti-CTLA-4 and anti-GITR mAbs to the sites where T cells and tumor antigen-loaded DC vaccines interact would enhance the induction of anti-tumor immunity while avoiding autoimmunity. To achieve this goal, DCs transfected with mRNA encoding the H and L chains of anti-mouse CTLA-4 and GITR mAbs were co-administered with tumor antigen mRNA-transfected DCs. We observed enhanced induction of anti-tumor immunity and significantly improved survival in melanoma-bearing mice, without signs of autoimmunity. Using in vitro assays with human DCs, we demonstrated that DCs transfected with mRNA encoding a humanized anti-CTLA-4 mAb and mRNA encoding a soluble human GITR-L fusion protein enhance the induction of anti-tumor CTLs in response to DCs transfected with mRNAs encoding either melanoma or breast cancer antigens. Based on these results, this approach of using local delivery of immune modulators to enhance vaccine-induced immunity is currently being evaluated in a phase I clinical cancer immunotherapy trial.
AuthorsScott K Pruitt, David Boczkowski, Nicole de Rosa, N Rebecca Haley, Michael A Morse, Douglas S Tyler, Jens Dannull, Smita Nair
JournalEuropean journal of immunology (Eur J Immunol) Vol. 41 Issue 12 Pg. 3553-63 (Dec 2011) ISSN: 1521-4141 [Electronic] Germany
PMID22028176 (Publication Type: Clinical Trial, Phase I, Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.)
CopyrightCopyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Chemical References
  • Antibodies, Monoclonal
  • Antigens, Neoplasm
  • CTLA-4 Antigen
  • Cancer Vaccines
  • Immunoglobulin Heavy Chains
  • Immunoglobulin Light Chains
  • RNA, Messenger
  • TNFSF18 protein, human
  • Tumor Necrosis Factors
Topics
  • Animals
  • Antibodies, Monoclonal (genetics, immunology, metabolism)
  • Antigens, Neoplasm (genetics, immunology, metabolism)
  • Autoimmunity (immunology)
  • CHO Cells
  • CTLA-4 Antigen (genetics, immunology, metabolism)
  • Cancer Vaccines (genetics, immunology, metabolism)
  • Cell Line, Tumor
  • Cricetinae
  • Dendritic Cells (immunology, metabolism)
  • Female
  • Humans
  • Immunoglobulin Heavy Chains (genetics, immunology, metabolism)
  • Immunoglobulin Light Chains (genetics, immunology, metabolism)
  • Melanoma, Experimental (genetics, immunology, metabolism, therapy)
  • Mice
  • Mice, Inbred C57BL
  • RNA, Messenger (genetics)
  • T-Lymphocytes, Cytotoxic (immunology, metabolism)
  • T-Lymphocytes, Regulatory (immunology, metabolism)
  • Transfection (methods)
  • Tumor Necrosis Factors (genetics, immunology, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: